Abstract
Cystic fibrosis (CF) is the most frequent lethal autosomal recessive disease among Caucasians. In more than 90% of all patients the pulmonary involvement is the life-limiting factor. In the lung, the production of viscous sputum is a main and early clinical feature of CF. To help clear the lungs from this material mucolytic active drugs were used. Recombinant human DNase (rhDNase) w1x and hypertonic (5.85%) saline (HS) w2x both were mucolytic active and improved FEV1 in the same range in patients with CF. Besides this similarity there are differences such as the modulation of rheological parameters and costs. To determine whether these treatments can replace each other, we compared effect and acceptance in the same group of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.